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A Randomized, Phase II Trial of Two Dose Levels of
Temsirolimus (CCI-779) in Patients with Extensive-Stage
Small-Cell Lung Cancer Who Have Responding or Stable
Disease after Induction Chemotherapy: A Trial of the
Eastern Cooperative Oncology Group (E1500)
Kishan J. Pandya, MD,* Suzanne Dahlberg, PhD,† Manuel Hidalgo, MD,‡ Roger B. Cohen, MD,§
Martin W. Lee, MD, Joan H. Schiller, MD,¶ and David H. Johnson, MD#
Hypothesis: To study the progression-free survival (PFS) and tox-
icity with 25- or 250-mg doses of temsirolimus (CCI-779) after
induction chemotherapy in patients with extensive small-cell lung
cancer.
Methods: Patients with either stable or responding disease to four to
six cycles of cisplatin or carboplatin plus etoposide or irinotecan
were randomized between 4 and 8 weeks after completion of
induction therapy to receive either 25 or 250 mg of temsirolimus
intravenously every week until disease progression.
Results: Eighty-seven patients entered between January 2002 and
December 2003, of whom 85 were eligible: 44 received 25 mg (arm
A), and 41 received 250 mg (arm B). The overall median follow-up
time for all eligible patients was 34.6 months. Median age was 59
years (range, 39–80); 42 (49.4%) were male and 43 (50.6%) female;
12.9% had brain metastases. The overall median and 1-year PFS
were 2.2 months (95% confidence interval [CI]: 1.8, 2.9) and 4.7%
(95% CI: 0.2%, 9.2%), respectively. The median PFS (95% CI) for
arm A was 1.9 months (1.6, 2.3); for arm B, it was 2.5 months (1.9,
3.4; p 0.24). The median overall survival from randomization was
8 months (95% CI: 6.5, 9.5). Among the 86 patients with reported
toxicities, 36 (42%) had grade 3 toxicities, the most common of
which were thrombocytopenia, hypophosphatemia, and fatigue, and
an additional 12 (14%) had grade 4 toxicities, the most common of
which was neutropenia. No patients experienced lethal toxicities.
Conclusion: Temsirolimus (CCI 779), given at 25 or 250 mg
weekly, seemed not to increase the PFS in this patient population.
Key Words: Small-cell lung cancer, Temsirolimus, CCI-779, Phase II
study.
(J Thorac Oncol. 2007;2: 1036–1041)
Lung cancer is the number one cause of cancer deaths inboth men and women in the United States. It was esti-
mated that approximately 174,470 new cases of lung cancer
would be diagnosed in the United States in 2006 and that
approximately 13% of these patients would have small-cell
lung cancer (SCLC).1 Histologically and biologically distinct,
SCLC displays rapid cell proliferation, abrupt clinical pre-
sentation, and a median survival of less than 3 months if left
untreated.2 Combination chemotherapy produces high initial
response rates, especially among patients with limited-stage
disease. Unfortunately, the disease invariably relapses, espe-
cially in patients with extensive-stage disease, causing death
of the patient. A search for newer approaches to improve
relapse-free and overall survival is clearly indicated for pa-
tients with extensive-stage SCLC.
Temsirolimus (CCI-779), an ester of sirolimus, is a novel
mammalian target of rapamycin inhibitor, with properties of a
cytostatic agent. It binds to and forms a complex with the
cytoplasmic protein, FK506 binding protein.3–5 This complex
inhibits mammalian target of rapamycin, which leads to the
inhibition of phosphorylation of the eukaryotic translation initi-
ation factor 4E binding protein-1 and the 40S ribosomal protein
p70 S6 kinase that regulate the progression of the cell cycle
from the G-1 to the S phase. In vitro, temsirolimus has
been shown to inhibit the growth of a number of hitologi-
cally diverse tumor cells, and in vivo antitumor activity in
early-phase clinical trials has been reported with temsiroli-
mus in patients with several tumor types,6 including renal
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cancer,7 breast cancer,8 and mantle cell lymphoma.9 These
studies have shown activity of temsirolimus at doses of 25,
75, and 250 mg/wk with an acceptable toxicity profile. None
of these studies were done in combination with standard
chemotherapy agents. This study was undertaken as part of
broad phase II exploration of this agent in solid tumors. It was
felt that as a “cytostatic” agent, it would be appropriate to use
it in a consolidation study design for SCLC.
The objectives of this clinical trial were to study pro-
gression-free survival (PFS) and determine toxicity in pa-
tients who received weekly doses of either 25 or 250 mg of




Patients were required to be older than 18 years old and
have histologically or cytologically confirmed SCLC of the
lung with extensive disease, defined as disease beyond the
hemithorax and adjacent nodes, supraclavicular node in-
volvement or pleural effusion with positive cytology, and a
performance status of 0, 1, or 2. Patients with limited disease
were ineligible. Patients were required to have received
induction chemotherapy with platinum (cisplatin or carbopla-
tin) plus either etoposide or irinotecan (minimum of three and
a maximum of six cycles), and show responding or stable
disease using the Response Evaluation Criteria in Solid Tu-
mors (RECIST) since the initiation of systemic chemotherapy
(i.e., patients who exhibited disease progression were not
eligible), and to have recovered from all toxicity related to
prior chemotherapy (except alopecia and/or neuropathy). Pa-
tients were allowed no fewer than 4 and no more than 8
weeks between the last induction chemotherapy treatment
and randomization and no more than 32 weeks between the
first dose of induction chemotherapy and date of randomiza-
tion. No prior treatment with biological response modifiers
was allowed. Patients with brain metastases were eligible as
long as they had received treatment, were asymptomatic and
were no longer taking corticosteroids or anticonvulsants.
Patients who developed brain metastases after completion of
induction chemotherapy were ineligible. Patients who were
immunocompromized, had an active infection or serious
intercurrent infection, or had received known immunosup-
pressive therapies within 3 weeks of randomization were
ineligible. Patients were required to practice adequate con-
traception and to not become pregnant during treatment.
Patients were required to have baseline measurements/eval-
uations of disease 4 weeks before randomization, and to
meet the following laboratory criteria (evaluated 2 weeks
before randomization): WBC 4000/mm or ANC 1500/mm
and platelet count 100,000/mm; total bilirubin 1.5 mg/dl;
creatinine 1.5 mg/dl; cholesterol level 350 mg/dl; and
trigylcerides 400mg/dl. All patients gave written informed
consent.
Patients who had not progressed entered the study
within 8 weeks of completing induction therapy and were
randomized to receive either 25 mg (arm A) or 250 mg (arm
B) of temsirolimus, given intravenously each week for 30
minutes until disease progression or unacceptable toxicity
(Figure 1). The National Cancer Institute Common Toxicity
Criteria version 2.0 were used to grade toxicity and to guide
dose modifications. Temsirolimus was held if the ANC was
1000/mm3 or platelets 80,000/mm3, and resumed at 75%
of the dose on full recovery for ANC between 750 and
999/mm3 or platelets between 50,000 and 80,000/mm3, and at
50% of the dose on full recovery for ANC 750/mm3 or
platelets 50,000/mm3. Temsirolimus was also held for any
grade 3 or 4 nonhematologic toxicity (except for nausea and
FIGURE 1. Schema.
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vomiting) and resumed at 75% for grade 3 and 50% for grade
4 after recovery to grade 0 to 2. After a dose reduction, no
dose escalation was allowed.
Disease assessment with appropriate imaging study was
required every 8 weeks, or sooner if clinical progression
became evident. As is the norm in all cooperative group
studies, there was no central review of imaging studies.
Statistical Considerations
Treatment assignments were determined using an on-
line, Web-based patient-registration program, stratifying on
brain metastases (yes versus no), prior chemotherapy for
induction (cisplatin or carboplatin) plus etoposide versus
cisplatin or carboplatin plus irinotecan), and response to
induction chemotherapy (complete recovery or partial recov-
ery versus stable disease).
The primary objective of this study was to test whether
a higher or lower dose of temsirolimus was better at prolong-
ing PFS in patients with extensive-stage SCLC who had
complete recovery, partial recovery, or stable disease after
induction chemotherapy and who had not progressed before
randomization to this trial. It was expected that the treatment
with a high dose of temsirolimus (250 mg, intravenously,
weekly) would result in more toxicities than the regimen with
a low dose (25 mg, intravenously, weekly). Hence, the high
dose of temsirolimus would only be investigated in a phase
III trial if it prolonged PFS to a sufficient extent. On the basis
of the median PFS time in the observation arm of E7593,10 it
was assumed that the median PFS time of the low-dose arm
of this trial would be at least 2.3 months. With 72 eligible
patients entered during 3 years and an additional 6 months of
follow-up, this design had 85% power to detect an increase in
median PFS time to 4 months in the high-dose arm (log–rank
test, one-sided significance level  0.1).
The secondary endpoint of this study was the determi-
nation of the toxicity rates of the two doses of temsirolimus.
In this analysis, any documented toxicity of grade 3 or higher
was considered. There was 86% power to detect a difference
in the true toxicity rates of 0.1 in the low-dose arm and 0.35
in the high-dose arm (Fisher exact test, one-sided significance
level  0.1).
Statistical Methods
PFS is defined as the interval from the date of entry
(randomization) on the study to the appearance of new
metastatic lesions or objective tumor progression or death
from any cause without progression. Overall survival is
defined as the time from date of entry (randomization) to
death from any cause. Patients without documented progres-
sion or death were censored at the time of the last docu-
mented disease evaluation.
Kaplan–Meier11 curves were used to estimate event–
time distributions. PFS was compared using log–rank tests.
Adverse events, patient demographics, disease characteris-
tics, and response rates were compared using Fisher exact
tests. All p values are two sided. Confidence intervals are at
the 95% level.
RESULTS
Between January 9, 2002 and December 9, 2003, 87
patients were entered on this study. One patient had no data
forms, and one patient was ineligible because of a diagnosis
of prostate cancer within the previous 5 years; these two cases
were removed from this analysis. The median follow-up of
eligible patients still alive was 34.6 months. At the time of
this analysis (June 19, 2006), four patients were still alive.
Patient demographic factors and disease characteristics for
the 85 eligible patients are shown in Table 1. The median age
was 59 years (range, 39–80). There were more female
patients (p  0.05) and more patients with brain metastases
on arm A (p  0.03). Among the 85 eligible patients, 76.8%
of them received at least two cycles of treatment with tem-
sirolimus (Table 2). Table 3 shows the reasons for treatment
termination, the distribution of which varied significantly
between the two arms (p  0.02). A higher proportion of
patients relapsed on the low-dose arm (65.1% versus 35.0%),
but a higher proportion of patients experienced high-grade
toxicity/side effects on the high-dose arm (40.0% versus
18.6%). Note that no reason for termination was provided for











Mean 61 59 60
Median 61 59 59
Range 42–78 39–80 39–80
Male 17 (38.6%) 25 (61.0%) 42 (49.4%)
Female 27 (61.4%) 16 (39.0%) 43 (50.6%)
White 37 (84.1%) 35 (85.4%) 72 (84.7%)
Black 1 (2.3%) 2 (4.9%) 3 (3.5%)
Other 6 (13.6%) 4 (9.8%) 10 (11.8%)
0 21 (47.7%) 17 (43.6%) 38 (45.8%)
1 21 (47.7%) 20 (51.3%) 41 (49.4%)
2 2 (4.6%) 2 (5.1%) 4 (4.8%)
Missing/unknown 0 2 2
Weight loss in previous
6 months
5% 35 (81.4%) 31 (77.5%) 66 (79.5%)
5%–10% 4 (9.3%) 8 (20.0%) 12 (14.5%)
10%–20% 4 (9.3%) 1 (2.5%) 5 (6.0%)
Missing/unknown 1 1 2
Type of induction chemotherapy
Platinum  etoposide 35 (79.5%) 34 (82.9%) 69 (81.2%)
Platinum  irinotecan 9 (20.5%) 7 (17.1%) 16 (18.8%)
Response to induction chemo
Complete recovery 9 (20.5%) 4 (10.0%) 13 (15.5%)
Partial recovery 23 (52.3%) 26 (65.0%) 49 (58.3%)
Stable disease 12 (27.3%) 10 (25.0%) 22 (26.2%)
Missing 0 1 1
Brain metastases
No 36 (81.8%) 38 (92.7%) 74 (87.1%)
Yes 8 (18.2%) 3 (7.3%) 11 (12.9%)
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eight patients; five of these patients were on the low-dose
arm, and three were on the high-dose arm.
PFS
There were 85 patients available for the primary anal-
ysis, 44 on the low-dose arm and 41 on the high-dose arm. All
but one patient on the low-dose arm had disease progression.
Figure 2A provides overall PFS, and Figure 2B provides PFS
by treatment. The overall median PFS was 2.2 months (95%
confidence interval [CI]: 1.8, 2.9), and the 1-year PFS rate
was 4.7% (95% CI: 0.2%, 9.2%). There is no evidence of a
difference in PFS between the two treatment arms: median
PFS  1.9 months (95% CI: 1.6, 2.3) for the low-dose arm,
and median PFS  2.5 months (95% CI: 1.9, 3.4) for
high-dose arm, log–rank p value  0.24. The resultant p
value corresponds to a one-sided p value of 0.12, which is
close to the one-sided   0.10 (p  0.1) significance level
specified in the study design. The median PFS of patients
entering the study with responding disease (partial recovery/
complete recovery) was 2.3 months (95% CI: 1.8, 3.3), and
the median PFS for those with stable disease was 1.9 months
(95% CI: 1.6, 2.2). The median PFS of patients without brain
metastases was 2.2 months (95% CI: 1.8, 2.3), and the
median PFS for those with brain metastases was 2.3 months
(95% CI: 1.2, 7.6). For males, the treatment differences were
significant (median PFS  1.7 months for the low-dose arm
and 3.0 months for the high-dose arm; p  0.03), but not for
females (median PFS 2.2 months for the low-dose arm and











1 14 (34.1%) 19 (46.3%) 33 (40.2%)
2 17 (41.5%) 13 (31.7%) 30 (36.6%)
3 2 (4.9% 3 (7.3%) 5 (6.1%)
4 3 (7.3%) 3 (7.3%) 6 (7.3%)
5 4 (9.8%) 1 (2.4%) 5 (6.1%)
6 0 (0%) 1 (2.4%) 1 (1.2%)
6 1 (2.4%) 1 (2.4%) 2 (2.4%)
Missing 3 0 3










Progression/relapse 28 (65.1%) 14 (35.0%) 42 (38.6%)
Toxicity/side effects 8 (18.6%) 16 (40.0%) 24 (28.9%)
Withdrawal/refusal 2 (4.7%) 6 (15.0%) 8 (9.6%)
Other complicating disease 0 (0%) 1 (2.5%) 1 (1.2%)
Missing/unknown 1 1 2
No reason was provided for eight patients: five on the lowdose arm, and three on
the high-dose arm.
FIGURE 2. Progression-free survival
(PFS) and survival: overall PFS (A), PFS
by treatment (B), overall survival (C),
and survival by treatment (D).
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1.9 months for the high-dose arm; p  0.86). There were no
differences based on race. Log–rank test results according to
gender and race are shown in Table 4.
Overall Survival
The median overall survival for the 85 eligible patients
was 8.0 months (95% CI: 6.5, 9.5; Figure 2C). The median
overall survival for the 44 patients on arm A was 6.6 months
(95% CI: 5.5, 8.9) and, for the 41 patients on arm B, 9.5
months (95% CI: 7.3, 13.3). One patient on arm A and three
patients on arm B had not died by the time of this analysis
(June 19, 2006). A log–rank test for the equality of the overall
survival distributions of arms A and B resulted in a p value of
0.008 (Figure 2D).
Objective Response
Responses were evaluated using RECIST. One patient
(1.2%) experienced a partial response among the 85 eligible
patients. Six patients (7.2%) experienced stable disease, and
74 patients (89.2%) experienced progressive disease.
Toxicity
Toxicity was evaluated by using the National Cancer
Institute Common Toxicity Criteria (version 2.0). Table 5
shows the incidence rates of grade 3 and 4 treatment-related
toxicities for 86 of 87 entered patients (no data were submit-
ted for one patient). Among the 86 patients with reported
toxicities, 36 (41.9%) had grade 3 toxicities, and the most
common grade 3 toxicities were thrombocytopenia, hy-
pophosphatemia, and fatigue. Twelve patients (14.0%) had
grade 4 toxicities, the most common of which was neutrope-
nia. No patient experienced lethal (grade 5) toxicity. Com-
paring toxicities between the treatment arms, 22 patients
(49.9%) had grade 3 or higher-grade toxicities on the low-
dose arm, and 26 patients (63.4%) had grade 3 or higher-
grade toxicities on the high-dose arm (p  0.20).
DISCUSSION
There has been a great deal of interest in “consolida-
tion” or “maintenance” treatment for SCLC, as patients who
respond to induction therapy invariably relapse at a later date.
So far, there is no evidence to support the use of prolonged
maintenance chemotherapy.12 It was hoped that a cytostatic
agent such as temsirolimus might provide prolongation of
PFS by suppressing the regrowth of cancer cells. The study
was a phase II exploratory design to see whether temsiroli-
mus at any of these two doses gave enough of a signal to
warrant a placebo-controlled phase III trial. In this population
of patients with extensive-stage SCLC, weekly “consolida-
tion” treatment with temsirolimus at 25 or 250 mg did not
seem to result in any improvement in PFS compared with
what was seen in the observation arm of E7593,10 which was
a prospective randomized study to determine whether topo-
tecan given after induction chemotherapy would result in
improved PFS compared with observation. PFS after induc-
tion chemotherapy in stable or responding patients was sig-
nificantly better with topotecan compared with observation
(3.6 versus 2.3 months; p  0.001); nevertheless, the overall
survival from randomization was not significantly different
(8.9 vs 9.3 months, respectively; p  0.43). The median PFS
of 2.2 months and the median overall survival of 8 months
after induction chemotherapy in the current study suggest a
lack of any meaningful clinical activity for temsirolimus in
this setting.
The estimated PFS hazard ratio (high dose/low dose)
among males was statistically significant (hazard ratio 
0.50; 95% CI: 0.26, 0.96), but it was not statistically signif-
icant among females (hazard ratio  1.06; 95% CI: 0.56,
1.98). The lack of stratification based on gender may be the









Overall 0.77 (0.50, 1.19) 0.24
Gender
Male 0.50 (0.26, 0.96) 0.03
Female 1.06 (0.56, 1.98) 0.86
Race
White 0.82 (0.52, 1.31) 0.41
Nonwhite 0.49 (0.14, 1.69) 0.25









3 (n) 4 (n) 3 (n) 4 (n)
Allergic reaction 1 — 1 —
Anemia 2 — 2 —
Neutropenia 4 1 1 4
Thrombocytopenia 3 — 7 2
Febrile neutropenia 1 — — —
Infection without neutropenia 1 — 3 —
Arrhythmia 1 — 1 —
Hypotension — — 1 —
Fatigue 2 — 6 —
Rash/desquamation 2 — 3 —
Urticaria — — 2 —
Stomatitis 1 — 3 —
Diarrhea 1 — 2 —
Hypercholesterolemia 1 — 3 —
Hyperglycemia — — 6 —
Hypertriglyceridemia 2 — 1 2
Hypocalcemia — — — 1
Hypophosphatemia 2 — 5 1
Conjunctivitis — — 1 —
Dyspnea 1 1 3 1
Hypoxia 1 — — 1
Pneumonitis/pulmonary infiltrates 1 — 2 1
Creatinine — 1 — —
Renal/GU—other — 1 — —
Total 19 3 17 9
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most likely explanation for this observation, although we
cannot completely rule out other explanations, because this
was a small phase II study.
Whereas a difference in the overall survival (6.6 versus
9.5 months) was observed in this study that was statistically
significant (p  0.008), it is largely attributable to a shorter
survival observed in the low-dose arm of only 6.6 months, as
compared with 8.9 months on the observation arm of E7593.
We do not have a satisfactory explanation for this observa-
tion. There were no obvious imbalances in the patient char-
acteristics between the arms that could explain this outcome.
There are significant differences between E7593 and the
current study. E7593 was a large phase III study that enrolled
patients before induction therapy. Thus, their performance
status was acceptable before induction chemotherapy, as
compared with patients entering the current study having
received their induction therapy in a nonstudy setting. Pa-
tients entering the second step of randomization of observa-
tion versus topotecan were, therefore, much more uniform
compared with patients entering this study. It is also possible
that second-line treatment could have played a role, but such
information was not collected.
Temsirolimus has shown activity in patients with
several tumor types,6 including renal cancer,7 breast can-
cer,8 and mantle cell lymphoma.9 Yet, it was found to have
little activity (5.6% objective response rate as assessed by
RECIST) in 37 patients with advanced progressive neu-
roendocrine carcinomas of either carcinoid or islet cell
carcinoma pathologies in a phase II study.13 It is possible
that temsirolimus has no activity in tumors of neuroendo-
crine origin.
In conclusion, temsirolimus given to responding or
stable patients with extensive-stage SCLC after induction
chemotherapy did not seem to result in any prolongation in
PFS compared with what has been reported in the literature.
Novel treatments that can prolong PFS and overall survival
are needed to improve the outcomes of this disease.
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